

JAN 09 2001

FORM PTO 449

US Dept. of Commerce
Patent and Trademark OfficeATTORNEY DOCKET NO.
4115-116 DIV 4SERIAL NO.
09/677,152INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

APPLICANT Gallo et al.

FILING DATE
October 2, 2000GROUP
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
js	AA	4,400,316	8/23/83	Katsuragi et al.			
	AB	4,689,222	8/25/87	McMichael			
	AC	4,691,006	9/1/87	Stevens			
	AD	4,692,332	9/8/87	McMichael			
	AE	4,713,366	12/15/87	Stevens			
	AF	4,714,680	12/22/87	Civin et al.			
	AG	4,880,626	11/14/89	McMichael			

RECEIVED

JAN 12 2001

TECH CENTER 1800/2000

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
js	AH	WO 90/02759	3/22/90	PCT				
	AI	WO 91/09872	7/11 /91	PCT				
	AJ	WO 92/22654	12/23/92	PCT				
	AK	WO 94/20859	9/15/94	PCT				
	AL	WO 94/24148	10/27/94	PCT				
	AM	WO 96/04008	2/15/96	PCT				

MOTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

js	AN	Abrams et al., 1983, J. Cell. Biochem. Supply A:53
	AO	Aizawa and Tavassoli, 1986, Int. J. Cell Cloning 4:464-471
	AP	Andrews et al., 1986, Blood 67:842-845
	AQ	Andrews et al., 1986, Blood 68:1030-1035
	AR	Ballem et al., 1987, J. Clin. Invest. 80:33-40
	AS	Ballem et al., 1992, New Eng. J. Med 327:1779-1784
	AT	Barre-Sinoussi et al., 1983 Science 220:868-870
	AU	Bauman et al., 1986, J. Cell Physiol. 128:133-142

Continue on Page 2

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

JAN 09 2001



INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000		GROUP


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
js	AV	4,966,753	10/30/90	McMichael			
	AW	5,004,681	4/2/91	Boyse et al.			
	AX	5,141,867	8/25/92	Ivanoff et al.			
	AY	5,192,553	3/9/93	Boyse et al.			
	AZ	5,380,668	1/10/95	Herron			
	BA	5,451,527	9/19/95	Sarin et al.			
	BB	5,610,136	3/11/97	McMichael			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
js	BC	0 049 898 B2	4/21/82	EP				
	BD	0 142 387 A1	5/22/85	EP				
	BE							
	BF							
	BG							
BH								

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

OTHER DOCUMENTS (Including Author, Title, Journal Date, Page)		
	BI	Bellet et al., 1984, Endocrinology 115:330-336
	BJ	Berchtold and Wenger, 1993, Blood 81:1246-1250
	BK	Bidart et al., 1987, Mol. Immunology 24:339-345
	BL	Bidart et al., 1987, J. Biol. Chem. 262:15483-15489
	BM	Bidart et al., 1990, Science 248:736-739
	BN	Blazevic et al., 1995, AIDS Res. Hum. Retroviruses 11:1335-1342
	BO	Bodger, et al., 1983, Blood 61:1006-1010
	BP	Bolognesi, 1993, Semin. Immunol. 5:203-214
BQ	Bourinbaier and Nagorny, 1992, FEMS Microbiol. Lett. 96:27-30	


Continue on Page 3

EXAMINER

DATE CONSIDERED

11/25/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000	GROUP	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
js	BR	5,677,275	10/14/97	Lunardi-Iskandar et al.			
	BS	5,700,781	12/23/97	P.J. Harris			
	BT	5,811,390	9/22/98	A.S. Bourinbaier	514	008	
	BU	5,614,612	3/25/97	Haigwood et al.			
	BV	5,494,899	2/27/96	Kincade et al.			
	BW	5,508,261	4/16/96	Moyle et al.			
	BX	5,635,599	6/3/97	Pastan et al.			
	BY	4,762,913	8/9/88	Stevens			
	BZ	4,767,842	8/30/88	Stevens			
	CA	4,855,285	8/8/89	Stevens			
	CB	4,161,519	7/17/79	Talwar			
	CC	4,780,312	10/25/88	Talwar			

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

OTHER DOCUMENTS (Including Author, Title, Journal, Date, Page)		
js	CD	Bourinbaier and Nagorny, 1992, FEBS Microbiol. Lett. 309:82-84
	CE	Bourinbaier and Lee-Huang, 1995, Immunol. Lett. 44:13-17
	CF	Braunstein et al., 1978, J. Clin. Endocrinology and Metabolism 47:326-332
	CG	Broxmeyer et al., 1984, J. Clin Invest. 73:939-953
	CH	Broxmeyer, 1983, CRC Critical Reviews in Oncology/Hematology 1:227-257
	CI	Broxmeyer, 1982, J. Clin Invest. 69:632-642
	CJ	Busch et al., 1987, Blut 54:179-188
	CK	Cain et al., 1986, Transplantation 41:22-25

Continue on Page 4

EXAMINER	DATE CONSIDERED 11/25/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000	GROUP	

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER INITIAL		
jo	CL	Cao et al., 1982, J. Med. Genet. 19:81-87
	CM	Caraux et al., 1985, J. Immun. 134:835-840
	CN	Chak et al., 1988, J. Clin. Oncol. 6:863-867
	CO	Chen et al., 1992, AIDS 6:533-539
	CP	Clavel et al., 1986, Science, 233-343-346
	CQ	Cocchi et al., 1995, Science, 270-1811-1815
	CR	Daffos, et al., 1983, am. J. Obstst. Gynecol. 146:985-987
	CS	Daffos, et al., 1985, am. J. Obstst. Gynecol. 153:655-660
	CT	Dalgleish et al., 1984, Nature 312: 763-767
	CU	De et al., 1997, J. Clin. Invest. 99:1484-1491
	CV	Delli-Bovi et al., 1986, Cancer Res. 46:6333-6338
	CW	Deshmukh et al., 1994, J. Clin. Immunol. 14:162-168
	CX	Dexter et al., 1977, J. Cell. Physiol. 91:335-344
	CY	Dickie et al, 1991, Virology, 185:109-119
	CZ	Dirnhofer et al. 1993, FASEB J. 7:1381-1385
	DA	Dirnhofer et al. 1994, J. Endocrinology 141:153-162
	DB	Emerson et al., 1985, J. Clin. Invest. 76:1286-1290
	DC	Ensoli et al., 1989, Science 243:223-226
	DD	Erickson, 1990, Science 249:527-533
	DE	Evans et al., 1991, J. Immunotherapy 10:39-50
DF	Ferrero et al., 1983, Proc Natl. Acad. Sci. USA 80:4114	
DG	Ferrero et al., 1986, Cancer Res. 46:975-980	
DH	Franks et al., 1995, Pediatric Res. 37:56-63	
DI	Friedman-Kien et al., 1981, J. Am. Acad. Dermatol. 5:468-473	
DJ	Gallo et al., 1984, Science 224:500-503	
DK	Gelmann et al., 1987, Am. J. Med. 82:456-462	

Continue on Page 5

EXAMINER	DATE CONSIDERED 11/25/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	




INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000		GROUP

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER INITIAL		
js	DL	Geller et al., 1985, Archs. Path. Lab. Met. 109:138-145
	DM	Gill et al., 1990, Am. J. Clin. Oncol. 13:315-319
	DN	Gill et al., 1991, Am. J. Med. 90:427-433
	DO	Gill et al., 1994, AIDS, 8: 1695-1699
	DP	Gill et al., 1996, New Eng. J. Med. 335:1261-1269
	DQ	Goldman et al., 1980, Br. J. Haematol. 45:221-223
	DR	Guyader et al., 1987, Nature 326:662-669
	DS	Hammerskjold and Rekosh, 1989, Biochem. Biophys. Acta 989:269-280
	DT	Harris, 1995, Lancet 346:118-119
	DU	Hermans, 1995, AIDS Res. Hum. Retroviruses S:96
	DV	Hermans et al., 1995, Cell. Mol. Biol. 3:357-364
	DW	Hershko et al., 1979, Lancet 1:945-947
	DX	Heymsfield et al., Am. J. Clin. Nutr. 36:Oct. 1982, p. 680-690
	DY	Hirokawa et al., 1982, Clin. Immunol. Immunopathol. 22:297-304
	DZ	Huang and Terstappen, 1992, Nature 360:745-749
	EA	Hutchinson et al., 1978, J. Biol. Chem. 253:6551-6560
	EB	Iyer et al. 1992, Int. J. Peptide Protein Res. 39:137-144
	EC	Juttner et al., 1985, Br. J. Haematol. 61:739-745
	ED	Kahn et al., 1990, am. Ann. Med. 112:254-261
	EE	Kardana et al., B. J. Cancer 1993 67:686-692
EF	Katz et al., 1985, Leukemia Res. 9:191-198	
EG	Katz et al., 1986, Leukemia Res. 10:961-971	
EH	Keating et al., 1984, Blood 64:1159-1162	
EI	Kestler et al., 990, Science 248:1109-1112	
EJ	Keutmann et al., 1987, Proc. Natl. Acad. Sci. USA 84:2038-2042	
EK	Keutmann et al., 1988, Biochemistry 27:8939-8944	
EL	Klatzmann et al., 1984, Nature 312:767-768	

Continue on Page 6

EXAMINER	DATE CONSIDERED 11/25/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	




INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000		GROUP

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER INITIAL		
EM	Kodo et al., 1984, J. Clin. Invest. 73:1377-1384	
EN	Kopp et al., 1993, AIDS Res. Hum. Retroviruses 9:267-275	
EO	Korbling et al., 1986, Blood 67:529-532	
EP	Korneyi et al., 1993, Biol. Reprod. 49:1149-1157	
EQ	Krown et al., 1990, Ann. Intern. Med. 112:812-821	
ER	Lajtha, 1979, Differentiation 14:23-34	
ES	Lajtha, 1979, Blood Cells 5:447-455	
ET	Laphorn et al., 1994, Nature 369:455-461	
EU	Leary et al., 1987, Blood 69:953-956	
EV	Letvin et al., 1990, J. AIDS 3:1023-1040	
EW	Longhi et al., 1986, J. Immunol. Meth. 92:89-95	
EX	Lord and Spooncer, 1986, Lymphokine Res. 5:59-72	
EY	Louache et al., 1992, Blood 180:2991-2999	
EZ	Lu et al., 1983, Blood 61:250-256	
FA	Lunardi-Iskandar at al., 1989, J. Clin. Invest. 83:610-615	
FB	Lunardi-Iskandar at al., 1989, Leukemia Res. 13:573-581	
FC	Lunardi-Iskandar at al., 1995, Nature 375:64-68	
FD	Maddon et al., 1986, Cell 47:333-348	
FE	Martin, 1991, <u>Basic and Chemical Endocrinology</u> (Appleton & Lange, East Norwalk) pp 543-567	
FF	Masood et al., 1984, AIDS Res. Hum. Retroviruses 10:969-976	
FG	McDougal et al., 1986, Science, 231:382-385	
FH	Merrifield, 1963, J. Amer. Chem. Soc. 85:2149-2156	
FI	Mitsuya et al., 1991, Science 249:1533-1544	
FJ	Moore et al., 1980, Blood 55:682-690	
FK	Nakamura et al., 1988, Science 242:426-430	
FL	Nicola et al., 1980, J. Cell. Physiol. 103:217-237	

Continue on Page 7

EXAMINER	DATE CONSIDERED 11/25/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	



INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4	SERIAL NO. 09/677,152
	APPLICANT Gallo et al.		
	FILING DATE October 2, 2000	GROUP	

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER INITIALS	FM	
	FN	Nicola et al., 1981, Blood 58:376-386
	FO	Nijhof et al., 1983, J. Cell. Biol. 96:386-392
	FP	Nijhof et al., 1984, Exp. Cell. Res. 155:583-587
	FQ	Nothdurft et al., 1977, Scand. J. Haematol. 19:470-481
	FR	Ochs et al., 1981, Pediatr. Res. 15:601
	FS	Paige et al., 1981, J. Exp. Med. 153:154-165
	FT	Paul, 1994, Cell 82:177-182
	FU	Perelson et al., 1966, Science 15:1582-1586
	FV	Pierce et al., 1991, Rev. Biochem., 50:465-495
	FW	Pillow et al., 1966, New Eng. J. Med. 275:94-97
	FX	Popescu et al., 1995, JNCI 88:450-454
	FY	Popovic et al., 1984, Science 224:497-500
	FZ	Prummer et al., 1985, Exp. Hematol. 13:891-898
	GA	Puisieux et al., 1990, Endocrinology 126:687-694
	GB	Raghavacher et al., 1983, J. Cell. Biochem. Suppl. 7A:78
	GC	Reiffers et al., 1986, Exp. Hematol. 14:312-315
	GD	Reisner et al., 1978, Proc. Natl. Acad. Sci. USA 75:2933-2936
	GE	Reisner et al., 1982, Blood 59:360-363
	GF	Robak et al., 1985, Leukemia Res. 9:1023-1029
	GG	Rodeck, 1984, <u>Prenatal Diagnosis</u> (Royal College of Obstetricians and Gynaecologists, London)
	GH	Ryan et al., 1988, FASEB J. 2:2661-2669
	GI	Salahuddin et al., 1988, Science 242:430-433
	GJ	Sarpel et al., 1979, Exp. Hematol. 7:113-120
	GK	Schall, 1991, Cytokine 3:165-183
	GL	Schooley et al., 1990, ann. Int. Med. 112:247-253
	GM	Sherman, 1992, J. Mol. Endocrinol. 6:951-959
		Siegel et al., 1990, Cancer 65:492-498

Continue on Page 8

EXAMINER	DATE CONSIDERED 11/25/02
----------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

JAN 09 2001
FORM PTO-49US Dept. of Commerce
Patent and Trademark OfficeATTORNEY DOCKET NO.
4115-116 DIV 4SERIAL NO.
09/677,152INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

APPLICANT Gallo et al.

FILING DATE
October 2, 2000

GROUP

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER INITIAL		
GN	Smith et al., 1987, Science 238:1704-1707	
GO	Smith and Broxmeyer, 1986, Br. J. Haematol. 63:29-34	
GP	Stevens et al., 1986, Immunol. Lett. 12:11-18	
GQ	Strauss et al., 1986, Exp. Hematol. 14:878-886	
GR	Strauss et al., 1986, Exp. Hematol. 14:935-945	
GS	Terstappen et al., 1992, Leukemia 6:993-1000	
GT	Thomas et al., 1972, Lancet 1(745):284-289	
GU	Tilly et al., 1986, Lancet, July 19 pp. 154-155	
GV	To and Juttner, 1987, Br. J. Haematol. 66:285-288	
GW	Torres et al., 1987, Immunol. Inv. 16:607-618	
GX	Touraine, 1983, Birth Defects 19:139-142	
GY	Triozi et al., 1994, Int. J. Oncol. 5:1447-1453	
GZ	Tulunay et al., 1975, Proc. Natl. Acad. Sci USA 72:4100-4104	
HA	Valenti, 1973, Am. J. Obstet. Gynecol. 115:851-853	
HB	Van Gemen et al., 1994, J. virol. Methods 49:157-168	
HC	Varmus et al., 1988, Science 240:1427-1439	
HD	Vaslin et al., 1994, AIDS Res. Hum. Retroviruses 10:1241-1250	
HE	Vickery et al., 1983, J. Parasitol. 69:478-485	
HF	Visser et al., 1984, J. Exp. Med. 59:1576-1590	
HG	Ward et al., 1991, <u>Reproduction in Domestic Animals</u> (Academic Press, New York) pp. 25-80	
HH	Weinroth et al., 1995, Infectious Agents and disease 4:76-94	
HI	Whitlock and Witte, 1982, Proc. Natl. Acad. Sci. USA 79:3608-3612	
HJ	Williams et al., 1987, Exp. Hematol. 15:243-250	
HK	Winchester et al., 1977, Proc. Natl. Acad. Sci. USA 74:4012-4016	
HL	Xia, 1993, J. Mol. Endocrinol., June 10:337-343	
HM	Yarchoan et al., 1989, Proc. Vth Int. Conf. On AIDS, p.564	
HN	Yunis, 1983, Science 221:227-236	

EXAMINER

DATE CONSIDERED

11/25/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

JAN 0 3 2001
FORM PTO 449US Dept. of Commerce
Patent and Trademark OfficeATTORNEY DOCKET NO.
4115-116 DIV 4SERIAL NO.
09/677,152INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

APPLICANT Gallo et al.

FILING DATE
October 2, 2000

GROUP

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER
INITIAL

HO

Kotler et al., Am. J. Clin. Nutr. 1985 42: 1255-65

HP

Kotler and Grunfeld, AIDS Wasting Syndrome, 229-275

HQ

Kotler et al., Am. J. Clin. Nutr. 1989; 50: 444-447

HR

Lunardi-Iskandar et al., J. Natl. Cancer Inst 87(13) 974-981

HS

Mastrangelo et al., Sem. Oncol 1996 23 (1): 4-21

HT

Mitsuya et al., FASEB 1991, 2369-2381

HU


Ott et al., Am J Clin Nutr 1993; 57:15-19

HV

Policastro et al., J Biol Chem 258: 11492-11499

HW

Russo and Russo, Cancer Letters 1995 90: 81-89


 11/25/02

JAN 09 2001
FORM PTO 449US Dept. of Commerce
Patent and Trademark OfficeATTORNEY DOCKET NO.
4115-116 DIV 4SERIAL NO.
09/677,152INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

APPLICANT Gallo et al.

FILING DATE
October 2, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
js	HX	5,455,968	Aug. 29, 1995	Blithe et al.	436	510	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
js	HY	0 211 411 A2	25 Feb 1987	Europe				
js	HZ	04300896	23 Oct 1992	Japan				
js	IA	WO87/03487	18 Jun 1987	PCT				

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

js	IB	Mastrangelo et al., 1996, "Gene therapy for human cancer; an essay for clinicians", Sem. Oncology 23:4-21
js	IC	Policastro et al., 1983, "The β subunit of human chorionic gonadotropin is encoded by multiple genes", J. Biol. Chem. 258:11492-11499
js	ID	Riddell et al., 1996, "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients", Nat. Med. 2:216-222


Continue on Page _____

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CFORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-116 DIV 4		SERIAL NO. 09/677,152	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		APPLICANT Gallo et al.		FILING DATE September 29, 2000	
		RECEIVED MAR 15 2001 CENTER 1600		GROUP 1648 Not Yet Assigned	




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
IR	Alfthan et al. (1992) Cancer Res. 52: 4628-4633.
IS	Bagshawe (1992) Acta Oncol. 31: 99-106.
IT	Bidart, J-M et al., "Human Chorionic Gonadotropin Molecular Forms, Detection, and Clinical Implications." TEM 4:285 (1993).
IU	Birken, S. et al., "Structure of the Human Chorionic Gonadotropin .beta.-Subunit Fragment from Pregnancy Urine." Endocrinology 123:572 (1988).
IV	Bourinbaiar, A.S. et al., "Pregnancy hormones, estrogen and progesterone, prevent HIV-1 synthesis in monocytes but not in lymphocytes." FEBS LETTERS 302:206 (1992).
IW	Chen, W. et al., "Recombinant Carbohydrate Variant of Human Choriogonadotropin .beta.-Subunit (hCG.beta.) Descarboxyl Terminus (115-145)." Journal of Biological Chemistry 266:6246 (1991).
IX	Cole, L.A., et al., "The Deactivation of hCG by Nicking and Dissociation" Journal of Clinical Endocrinology and Metabolism 76:704 (1993).
IY	Cole, Laurence A. et al., "The Heterogeneity of Human Chorionic Gonadotropin (hCG). III. The Occurrence and Biological and Immunological Activities of Nicked hCG." Endocrinology 129:1559 (1991).
IZ	Curti, Critical Reviews in Oncology/Hematology, vol.14, pp. 29-39, 1993.
JA	Danforth, D.N., Jr., M.D., "How Subsequent Pregnancy Affects Outcome in Women with a Prior Breast Cancer." Oncology 5:23 (1991).
JB	Elford et al. (1993) AIDS 7: 1667-1671.
JC	Freireich, E.J. et al., "Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man." Cancer Chemotherapy Reports 50:219 (1966).
JD	Hirabayashi, M., M.D., "Early Gastric Cancer and a Concomitant Pregnancy", The American Surgeon 53:730 (1987).
JE	Huang, J. et al., "Amino/Carboxyl-terminal Deletion Mutants of Human Choriogonadotropin .beta.." The Journal of Biological Chemistry 268:9311 (1993).
JF	Huang, J. et al., "Mutagenesis of the 'determinant loop' region of human choriogonadotropin .beta.." Molecular and Cellular Endocrinology 90:211 (1993).
JG	Jain, Scientific American, pp. 58-65, Jul. 1994.

Continue on Page 2

EXAMINER	DATE CONSIDERED
	11/25/02

EKXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CFORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		4115-116 DIV 4	09/677,152
		APPLICANT	
		Gallo et al.	
		FILING DATE	GROUP
		September 29, 2000	Not Yet Assigned

JH	Kumar, S. et al., "Necrosis and Inhibition of Growth of Human Lung Tumor by Anti- α -Human Chorionic Gonadotropin Antibody." J. Natl Cancer Inst. 84:42 (1992).
JI	Loosfelt, H. et al., "Cloning and Sequencing of Porcine LH-hCG Receptor cDNA: Variants Lacking Transmembrane Domain." Science 245:525 (1989).
JJ	Mann et al, Scand. J. Clin. Lab. Invest. , Suppl. vol. 216, pp. 97-104, 1993.
JK	Marcillac et al. (1992) Cancer Res. 52: 3901-3907.
JL	McFarland, K.C. et al., "Lutropin-Choriogonadotropin Receptor: An Unusual Member of the G Protein-Coupled Receptor Family." Science 245:494 (1989).
JM	Nakhai, B. et al., "Over-expression and characterization of recombinant beta subunit of the human chorionic gonadotropin hormone synthesized in insect cells infected with a genetically engineered baculovirus." Indian Journal of Biochemistry & Biophysics 29:315 (1992).
JN	Northfeldt et al. (1991) Hematology/Oncology Clinics of North America 5: 297-310.
JO	Ozturk, M. et al., "Ectopic β -Human Chorionic Gonadotropin Production by a Human Hepatoma Cell Line (FOCUS): Isolation and Immunochemical Characterization." Endocrinology 120:559 (1987).
JP	Ozturk, M. et al., "Physiological Studies of Human Chorionic Gonadotropin (hCG), α -hCG, and β -hCG as Measured by Specific Monoclonal Immunoradiometric Assays." Endocrinology 120:549 (1987).
JQ	Ross et al., Immunology Today, vol. 11, No. 6, 1990.
JR	Siemen, Rodent Tumor Models in Experimental Cancer Therapy, Edited by Kallman, Pergamon Press, pp. 12-15, 1987.
JS	Sridhar, P. et al., "Differential secretion and glycosylation of recombinant human chorionic gonadotropin (β -hCG) synthesized using different promoters in the baculovirus expression vector system." Gene (Netherlands) 131:261 (1993).
JT	Stenman et al. (1993) Scand. J. Clin. Lab. Invest. Suppl. 216: 42-78.
JU	Strickland et al. in Luteinizing hormone action and receptors, M. Ascoli, Ed., CRC Press, Boca Raton FL, 1985, p. 1.
JV	Trott, Rodent Tumor Models in Experimental Cancer Therapy, Edited by Kallman, Pergamon Press, pp. 6-11, 1987.
JW	Ward et al. in Reproduction in Domestic Animals, 4th ed., Cuppos, PT, ed., pp. 25-80, Academic Press, NY (1991).
JX	Wass, M. et al., "Response of lymphocytes from cancer patients to human *chorionic* gonadotrophin", Lancet (England) 1:8004:171 (1977).
JY	Yano, T. et al., "Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone." Proc. Natl. Acad. Sci. USA 91:1701 (1994).

Continued on Page _____

EXAMINER <i>J. Stucker</i>	DATE CONSIDERED 11/25/02
-------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CFORM PTO-1449 US Dept. of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	ATTORNEY DOCKET NO.	SERIAL NO.
	4115-116 DIV 4	09/677,152
	APPLICANT	
	Gallo et al.	
	FILING DATE	GROUP
	October 2, 2000	1648

 RECEIVED
 AUG 23 2001
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>js</i>	KA	4,201,770	5/6/80	Stevens	424	177	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
<i>js</i>	KB	WO9108228	6/13/91	PCT	7	10		X
	KC	WO9749373	12/31/97	PCT	A61K		X	
	KD	WO9906438	2/11/99	PCT	14	00	X	
	KE	WO9222568	12/23/92	PCT	3	00	X	
	KF	WO9925849	5/27/99	PCT	15	62	X	
	KG	0323769	11/25/88	Europe	7	06		X

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

<i>js</i>	KH	Fink, et al., Amino Acid Sequence Elucidation of Human Acrosin-Trypsin Inhibitor (HUSI-II) Reveals that Kazal-type Proteinase Inhibitors are Structurally Related to β -subunits of Glycoprotein Hormones, FEBs Letters, Volume 270, number 1, 2, ppg. 222-224

Continue on Page _____

EXAMINER	DATE CONSIDERED
<i>js</i>	11/25/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CFORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-116 DIV4		SERIAL NO. 09/677,152	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Gallo et al.			
				FILING DATE October 2, 2000		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		/					
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JE	IE	WO 86/04241	31 Jul 1986	PCT	—	—	
JE	IF	WO 91/16921	14 Nov 1991	PCT	—	—	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
JE	IG	Cole, L.A. "The heterogeneity of human gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG," Endocrinology, 1991 Sep, 129 (3):1559-1567					
	IH	Cole, L.A. et al., "The biological and clinical significance of nicks in human chorionic gonadotropin and its free beta-subunit," Yale J Biol Med 1991 Nov-Dec; 64 (6):627-37					
	II	Cole, Laurence A. "hCG, Its Free Subunits and Its Metabolites -- Roles in Pregnancy and Trophoblastic Disease," Journal of Reproductive Medicine, 1998 Jan, 43 (1): 3-10					
	IJ	Creighton, 1993, Proteins, Structures and Molecular Principles (W.H. Freeman & Co., New York) pp.34-49					
	IK	Dirnhofer, S. et al., "Functional and immunological relevance of the COOH-terminal extension of human chorionic gonadotropin beta: implications for the WHO birth control vaccine," FASEB J 1993 Nov; 7(14):1381-1385					
	IL	Ho, H.H. et al., "Characterization of human chorionic gonadotropin peptide variants with a radio-receptor assay using recombinant human luteinizing hormone/chorionic gonadotropin receptors," Early Pregnancy 1997 Sep, 3 (3):204-12					
	IM	Iyer, K.S. et al., "Search for peptide immunogens of the beta-subunit of human chorionic gonadotropin (hCG) capable of eliciting hormone specific and neutralizing antisera. Identification of an undecapeptide eliciting hCG-specific antisera," Int J Pept Protein Res 1992 Feb: 39(2):137-44					
	IN	James, John S. "New Approaches to HIV Treatment: Interview with Robert Gallo, M.D.," Aids Treatment News, Dec 19, 1997, Issue 285, pp.1-7 (www.immunet.org)					
	IO	Kardana, A. et al., "Human chorionic gonadotropin beta-subunit nicking enzymes in pregnancy and cancer patient serum," J Clin Endocrinol Metab, 1994 Sep, 79 (3):761-7					
	IP	"Chorionic Gonadotropin," U.S. Pharmacopia (USP23)					
	IQ	Kobata, Akira et al., "Structure, pathology and function of the N-linked sugar chains of human chorionic gonadotropin," Biochemica et Biophysica Acta 1455 (1999) 315-326					
Continue on Page _____							
EXAMINER <i>J. Stucker</i>					DATE CONSIDERED 11/25/02		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							